Hip kinetics during gait are clinically meaningful outcomes in young boys with Duchenne muscular dystrophy.
暂无分享,去创建一个
C. Buckon | M. Sussman | E. Fowler | S. Sienko | C. McDonald | A. Bagley | K. Heberer | M. Sison-Williamson | L. Staudt
[1] H. Hillege,et al. European Medicines Agency review of ataluren for the treatment of ambulant patients aged 5 years and older with Duchenne muscular dystrophy resulting from a nonsense mutation in the dystrophin gene , 2015, Neuromuscular Disorders.
[2] A. Mayhew,et al. Measuring clinical effectiveness of medicinal products for the treatment of Duchenne muscular dystrophy , 2015, Neuromuscular Disorders.
[3] T. Partridge,et al. What Can We Learn From Clinical Trials of Exon Skipping for DMD? , 2014, Molecular therapy. Nucleic acids.
[4] E. Hoffman,et al. Pharmacologic management of Duchenne muscular dystrophy: target identification and preclinical trials. , 2014, ILAR journal.
[5] Jay J. Han,et al. The cooperative international neuromuscular research group Duchenne natural history study: Glucocorticoid treatment preserves clinically meaningful functional milestones and reduces rate of disease progression as measured by manual muscle testing and other commonly used clinical trial outcome measur , 2013, Muscle & nerve.
[6] S. Pandya,et al. Review of Phase II and Phase III clinical trials for Duchenne muscular dystrophy , 2013 .
[7] Francesco Muntoni,et al. Development of a functional assessment scale for ambulatory boys with Duchenne muscular dystrophy. , 2012, Physiotherapy research international : the journal for researchers and clinicians in physical therapy.
[8] E. Pavan,et al. Early signs of gait deviation in Duchenne muscular dystrophy. , 2011, European journal of physical and rehabilitation medicine.
[9] S. Gasperini,et al. Functional changes in Duchenne muscular dystrophy , 2011, Neurology.
[10] E. Hoffman,et al. Restoring dystrophin expression in duchenne muscular dystrophy muscle progress in exon skipping and stop codon read through. , 2011, The American journal of pathology.
[11] S. Õunpuu,et al. Efficacy of clinical gait analysis: A systematic review. , 2011, Gait & posture.
[12] K. Wagner. Approaching a new age in Duchenne muscular dystrophy treatment , 2008, Neurotherapeutics.
[13] F. Muntoni,et al. The status of exon skipping as a therapeutic approach to duchenne muscular dystrophy. , 2011, Molecular therapy : the journal of the American Society of Gene Therapy.
[14] Jay J. Han,et al. The 6‐minute walk test in Duchenne/Becker muscular dystrophy: Longitudinal observations , 2010, Muscle & nerve.
[15] C. Schmoor,et al. Treatment of Duchenne muscular dystrophy with ciclosporin A: a randomised, double-blind, placebo-controlled multicentre trial , 2010, The Lancet Neurology.
[16] S. Nadeau,et al. Gait patterns comparison of children with Duchenne muscular dystrophy to those of control subjects considering the effect of gait velocity. , 2010, Gait & posture.
[17] A. Nicorici,et al. Classification of the Gait Patterns of Boys With Duchenne Muscular Dystrophy and Their Relationship to Function , 2010, Journal of child neurology.
[18] Jay J. Han,et al. The 6‐minute walk test as a new outcome measure in Duchenne muscular dystrophy , 2010, Muscle & nerve.
[19] R. Finkel,et al. Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management , 2010, The Lancet Neurology.
[20] Anna Carla Turconi,et al. Gait pattern in Duchenne muscular dystrophy. , 2009, Gait & posture.
[21] C. Angelini. The role of corticosteroids in muscular dystrophy: A critical appraisal , 2007, Muscle & nerve.
[22] Victoria L Chester,et al. A comparison of kinetic gait parameters for 3-13 year olds. , 2006, Clinical biomechanics.
[23] D. Matthews,et al. Corticosteroid Treatment and Functional Improvement in Duchenne Muscular Dystrophy: Long-Term Effect , 2005, American journal of physical medicine & rehabilitation.
[24] J. Fock,et al. Functional ability and muscle force in healthy children and ambulant Duchenne muscular dystrophy patients. , 2005, European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society.
[25] Eric Watelain,et al. A comparison of gait in spinal muscular atrophy, type II and Duchenne muscular dystrophy. , 2004, Gait & posture.
[26] R. Abresch,et al. Profiles of neuromuscular diseases. Becker's muscular dystrophy. , 1995, American journal of physical medicine & rehabilitation.
[27] R. Abresch,et al. Becker's muscular dystrophy , 1995 .
[28] J. Hsu,et al. Gait and Posture Changes in the Duchenne Muscular Dystrophy Child , 1993, Clinical orthopaedics and related research.
[29] J. Miller,et al. Randomized, double-blind six-month trial of prednisone in Duchenne's muscular dystrophy. , 1989, The New England journal of medicine.
[30] R. Olshen,et al. The Pathomechanics of Gait in Duchenne Muscular Dystrophy , 1981, Developmental medicine and child neurology.